|
Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (AR) ligand-binding domain (LBD) mutations. |
|
|
Consulting or Advisory Role - Seattle Genetics/Astellas |
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Blueprint Medicines |
|
|
Employment - Genesis Research |
|
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
Travel, Accommodations, Expenses - Guardant Health |
|
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
Patents, Royalties, Other Intellectual Property - RWE selection patent application pending |
Travel, Accommodations, Expenses - Guardant Health |
|
|
Stock and Other Ownership Interests - Bellerophon Theraeutics; Pfizer; Regeneron |
Consulting or Advisory Role - Akebia Therapeutics; Arvinas; Beam Therapeutics; Bellus Health; Novartis; Novo Nordisk; Pfizer; Sanofi |
|
|
Employment - Genesis Research |
|
|
|
Stock and Other Ownership Interests - Arvinas |
|
|
Employment - Arvinas; Merck (I) |
Stock and Other Ownership Interests - Arvinas; Merck (I) |
|
|
Stock and Other Ownership Interests - Salus Discovery |
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Gilead Sciences; Immunomedics; Janssen; Pfizer/Astellas; Pfizer/Myovant; Sanofi |
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst) |
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available. |